Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NexStar Pharm(NXTR) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (240)	11/18/1997 10:08:00 AM
From: Biomaven	Read Replies (2) \| Respond to of 328

Miljenko: I agree this release is not very well written. My interpretation: Both groups will be getting MiKasome. As there are only 15 people in each group, I would assume that they will not try different single doses in the second group. I'm curious why they chose to do this particular trial. Presumably the single infusion is not going to be safer or more efficaceous than the multiple day infusions, so they seem to be focussing on cost and ease of administration rather than on safety/efficacy. This _may_ mean they are fairly confident that it's going to work and be safe. On the other hand, the Phase III would presumably be against daily Amikacin, and so why not just go with daily MiKasome? (And do a follow-on study once it is approved to get a single-infusion protocol approved). Peter